BioNTech SE (BNTX)
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
What Makes BioNTech (BNTX) a New Buy Stock
BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever.
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioNTech initiated with a Buy at Truist
Truist initiated coverage of BioNTech with a Buy rating and $172 price target. BioNTech is an oncology company "at heart, even though it was the COVID vaccine that made it a household name," the analyst tells investors in a research note. The firm says that with the pandemic in the rear-view mirror, investor focus is increasingly shifting to BioNTech's oncology business. It says 2025 is set up with potentially stock-moving read-outs for key assets, presenting "ample opportunity" for BioNTech to grow into the price target.
5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right
Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023.
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine, the company said in filings on Friday.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
US FDA lifts partial clinical hold on BioNTech cancer drug study
BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a type of lung cancer.
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond.
